Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib MRI response timing in rheumatoid arthritis
ACTRN12622000032752Phase 4Terminated
- Sponsor
- Emeritus Research
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of upadacitinib in rheumatoid arthritis (RA), sponsored by Emeritus Research. Primary endpoint: MRI findings by RAMRIS in the selected hand/wrist at week 24. Started Jun 2022; status: terminated.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ACTRN12622000032752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000032752.